Skip to main content
Caplight Logo









Immunexpress

Immunexpress

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://immunexpress.com/

Last Round

Grant

Jun 16, 2020

Total Funding Raised

$9.42M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Immunexpress is a biotechnology company that develops and commercializes molecular diagnostic technologies designed for the early detection of sepsis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

sepsis testmolecular diagnosticshost responserapid diagnosticssepsis diagnosisgene expression analysisin vitro diagnosticsIVDcritical care diagnosticssepsis biomarkersystemic inflammatory response syndromeSIRSantibiotic stewardshipdiagnostic cartridgeprecision medicineFDA cleared

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Immunexpress Comparables

Compare Immunexpress with similar companies based on industry and business-model similarity.

Immunexpress comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ASEP Medical Holdings Inc.
78%
GenomeKey
74%
Inflammatix
74%

Immunexpress Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 16, 2020
VC RoundOct 3, 2019
GrantFeb 6, 2019
Series AMar 5, 2014
Private EquityJun 19, 2012

Key People

Founding team and executive leadership

Rollie Carlson

CEO

Executive Team

Immunexpress Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 236% MoM, reaching 1.5K.

  • Jun 1, 2025

    Monthly visitors grew 194% MoM, reaching 2.5K.

Immunexpress Filings

Explore SEC and related filing metadata, where available.

Immunexpress filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Immunexpress's valuation, stock price, and market status.

Is Immunexpress a public or private company?

Immunexpress is a private company.

What is the current stock price of Immunexpress?

Immunexpress is a private company with no public stock price. No recent secondary market data is available.

How much is Immunexpress worth (valuation)?

Valuation information for Immunexpress is not publicly available.

Can I buy Immunexpress stock?

Immunexpress shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Immunexpress's last funding round?

Immunexpress's most recent funding round was Grant on June 16, 2020.

Who are the main investors in Immunexpress?

Key investors in Immunexpress include U.S. Department of Health and Human Services, Public Health Emergency Medical Countermeasures Enterprise.

Will Immunexpress IPO soon?

No public IPO plans have been announced for Immunexpress.

How can I track Immunexpress secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Immunexpress's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range11
Year Founded2006
Last FundingJun 16, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?